https://www.proteomedix.com/en/2023-08-24monthly0.5https://www.proteomedix.com/en/science/2020-06-26monthly0.5https://www.proteomedix.com/en/company/2026-08-07monthly0.5https://www.proteomedix.com/en/news/2020-07-07monthly0.5https://www.proteomedix.com/en/contact/2023-12-17monthly0.5https://www.proteomedix.com/en/meta/2020-01-28monthly0.5https://www.proteomedix.com/en/privacy-policy/2022-05-04monthly0.5https://www.proteomedix.com/en/site-notice/2022-05-04monthly0.5https://www.proteomedix.com/en/news/54/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-agmonthly0.5https://www.proteomedix.com/en/news/53/onconetix-announces-two-peer-reviewed-publications-supporting-the-clinical-utility-of-proclarix-in-early-prostate-cancer-diagnosis-and-active-surveillancemonthly0.5https://www.proteomedix.com/en/news/50/onconetix-announces-its-subsidiary-proteomedix-licenses-manufacturing-ip-to-immunovia-enabling-them-to-independently-produce-key-reagents-for-their-pancreatic-cancer-test-pancreasuremonthly0.5https://www.proteomedix.com/en/news/51/onconetix-announces-successful-clinical-validation-of-its-innovative-prostate-cancer-test-proclarix-in-a-danish-cohortmonthly0.5https://www.proteomedix.com/en/news/52/onconetix-announces-new-clinical-data-for-its-innovative-prostate-cancer-test-proclarix-accepted-for-presentation-at-2025-european-association-of-urology-congressmonthly0.5https://www.proteomedix.com/en/news/49/proteomedix-acquired-by-blue-water-biotech-to-form-onconetix-inc-a-commercial-stage-mens-health-pharma-and-diagnostics-companymonthly0.5https://www.proteomedix.com/en/news/48/results-published-evaluating-proclarix-in-the-diagnostic-work-up-of-prostate-cancermonthly0.5https://www.proteomedix.com/en/news/47/proteomedix-appoints-ralph-schiess-as-ceomonthly0.5https://www.proteomedix.com/en/news/44/proteomedix-agrees-to-issue-labcorp-exclusive-license-for-proclarix-blood-test-to-detect-prostate-cancermonthly0.5https://www.proteomedix.com/en/news/46/american-urology-association-includes-proclarix-in-the-2023-guidelinemonthly0.5https://www.proteomedix.com/en/news/45/proclarix-included-in-the-2023-european-association-of-urology-guidelinesmonthly0.5https://www.proteomedix.com/en/news/43/results-published-demonstrating-accurate-diagnosis-of-prostate-cancer-by-combining-proclarix-with-magnetic-resonance-imagingmonthly0.5https://www.proteomedix.com/en/news/42/proteomedix-receives-ivdr-certification-for-proclarixmonthly0.5https://www.proteomedix.com/en/news/41/proteomedix-announces-grant-of-chinese-patent-on-proclarixmonthly0.5https://www.proteomedix.com/en/news/40/side-by-side-evaluation-of-proclarix-and-the-prostate-health-index-phi-for-the-identification-of-clinically-significant-prostate-cancermonthly0.5https://www.proteomedix.com/en/news/39/proteomedix-announces-grant-of-us-patent-on-proclarixmonthly0.5https://www.proteomedix.com/en/news/38/new-results-on-proclarix-resolving-indeterminate-magnetic-resonance-imaging-mri-for-improved-prostate-cancer-diagnosis-will-be-presented-at-the-37th-annual-eau-congress-in-amsterdam-nlmonthly0.5https://www.proteomedix.com/en/news/37/the-biodiagnostica-montevergine-malzoni-network-in-mercogliano-will-introduce-proclarix-into-its-laboratory-routinemonthly0.5https://www.proteomedix.com/en/news/36/new-clinical-data-published-from-proclarix-together-with-magnetic-resonance-imaging-mri-for-improved-prostate-cancer-diagnosismonthly0.5https://www.proteomedix.com/en/news/35/clinical-data-published-of-a-novel-serum-biomarker-quintet-that-improves-disease-prognosis-in-men-with-confirmed-prostate-cancermonthly0.5https://www.proteomedix.com/en/news/34/proteomedix-presents-at-the-annual-congress-of-the-italian-society-of-urology-in-riccione-and-the-society-of-urologists-in-private-hospitals-in-modenamonthly0.5https://www.proteomedix.com/en/news/33/proteomedix-praesentiert-sich-an-der-jahresversammlung-der-schweizerischen-gesellschaft-fuer-urologie-in-interlakenmonthly0.5https://www.proteomedix.com/en/news/32/proteomedix-and-new-horizon-health-limited-enter-into-a-research-and-development-partnershipmonthly0.5https://www.proteomedix.com/en/news/31/proteomedix-praesentiert-sich-am-jahreskongress-der-deutschen-gesellschaft-fuer-urologie-in-stuttgartmonthly0.5https://www.proteomedix.com/en/news/30/new-spanish-clinical-data-from-proclarix-together-with-magnetic-resonance-imaging-mri-for-improved-prostate-cancer-diagnosis-will-be-presented-at-the-36th-annual-european-urology-congressmonthly0.5https://www.proteomedix.com/en/news/29/university-of-naples-federico-ii-is-implementing-and-evaluating-proclarix-to-make-it-available-in-italymonthly0.5https://www.proteomedix.com/en/news/27/zhengzhou-university-henan-cancer-hospital-zuhch-and-proteomedix-enter-into-a-cooperation-to-clinically-validate-biomarker-tests-and-bioinformatics-for-prostate-cancer-diagnosticsmonthly0.5https://www.proteomedix.com/en/news/26/results-published-of-propose-a-real-life-prospective-study-of-proclarix-a-novel-blood-based-test-to-support-challenging-biopsy-decision-making-in-prostate-cancermonthly0.5https://www.proteomedix.com/en/news/25/swiss-center-for-laboratory-medicine-st-gallen-presents-data-from-proclarix-at-american-association-for-clinical-chemistry-aacc-annual-scientific-meetingmonthly0.5https://www.proteomedix.com/en/news/24/university-hospital-frankfurt-mvz-gmbh-first-laboratory-offering-proclarix-in-germanymonthly0.5https://www.proteomedix.com/en/news/23/bestaetigung-der-diagnostischen-leistungsfaehigkeit-des-ersten-schweizer-tests-zur-biopsie-entscheidung-in-der-prostatakrebs-diagnostikmonthly0.5https://www.proteomedix.com/en/news/21/verbesserte-prostatakrebsdiagnostik-ein-ueberblick-im-magazin-der-schweizerischen-union-fuer-labormedizinmonthly0.5https://www.proteomedix.com/en/news/20/proteomedix-appoints-dr-maurizio-ballerini-md-as-vp-market-development-emea-and-dr-helene-peyro-saint-paul-md-as-medical-advisormonthly0.5https://www.proteomedix.com/en/news/19/analytical-performance-of-proclarix-verifiedmonthly0.5https://www.proteomedix.com/en/news/18/proteomedix-and-dynex-technologies-enter-into-strategic-alliance-to-provide-automated-workflows-for-proclarixmonthly0.5https://www.proteomedix.com/en/news/7/center-for-laboratory-medicine-st-gallen-is-the-first-laboratory-to-offer-proclarixmonthly0.5https://www.proteomedix.com/en/news/12/proteomedix-announces-commercial-launch-of-proclarix-in-europemonthly0.5https://www.proteomedix.com/en/news/22/new-data-from-proclarix-together-with-magnetic-resonance-imaging-mri-for-improved-prostate-cancer-diagnosis-to-be-showcased-at-american-society-of-clinical-oncology-asco-genitourinary-cancers-symposiummonthly0.5https://www.proteomedix.com/en/news/1/proteomedix-appoints-helge-lubenow-as-new-ceomonthly0.5https://www.proteomedix.com/en/news/2/proteomedix-today-announced-the-appointment-of-prof-em-dr-med-thomas-cerny-as-new-member-of-the-board-of-directorsmonthly0.5https://www.proteomedix.com/en/news/3/new-publication-confirms-that-the-use-of-proteomedix-proprietary-blood-based-biomarkers-improves-clinically-significant-prostate-cancer-diagnosismonthly0.5https://www.proteomedix.com/en/news/4/proteomedix-raises-chf-52-million-in-financing-roundmonthly0.5https://www.proteomedix.com/en/news/5/novel-biomarker-test-avoids-biopsies-by-accurately-predicting-high-grade-prostate-cancermonthly0.5https://www.proteomedix.com/en/news/6/new-publication-describes-the-development-and-clinical-testing-of-proteomedix-immunoassays-for-prostate-cancer-diagnosismonthly0.5https://www.proteomedix.com/en/news/54/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-agmonthly0.5https://www.proteomedix.com/en/news/53/onconetix-announces-two-peer-reviewed-publications-supporting-the-clinical-utility-of-proclarix-in-early-prostate-cancer-diagnosis-and-active-surveillancemonthly0.5https://www.proteomedix.com/en/news/50/onconetix-announces-its-subsidiary-proteomedix-licenses-manufacturing-ip-to-immunovia-enabling-them-to-independently-produce-key-reagents-for-their-pancreatic-cancer-test-pancreasuremonthly0.5https://www.proteomedix.com/en/news/51/onconetix-announces-successful-clinical-validation-of-its-innovative-prostate-cancer-test-proclarix-in-a-danish-cohortmonthly0.5https://www.proteomedix.com/en/news/52/onconetix-announces-new-clinical-data-for-its-innovative-prostate-cancer-test-proclarix-accepted-for-presentation-at-2025-european-association-of-urology-congressmonthly0.5https://www.proteomedix.com/en/news/49/proteomedix-acquired-by-blue-water-biotech-to-form-onconetix-inc-a-commercial-stage-mens-health-pharma-and-diagnostics-companymonthly0.5https://www.proteomedix.com/en/news/48/results-published-evaluating-proclarix-in-the-diagnostic-work-up-of-prostate-cancermonthly0.5https://www.proteomedix.com/en/news/47/proteomedix-appoints-ralph-schiess-as-ceomonthly0.5https://www.proteomedix.com/en/news/44/proteomedix-agrees-to-issue-labcorp-exclusive-license-for-proclarix-blood-test-to-detect-prostate-cancermonthly0.5https://www.proteomedix.com/en/news/46/american-urology-association-includes-proclarix-in-the-2023-guidelinemonthly0.5https://www.proteomedix.com/en/news/45/proclarix-included-in-the-2023-european-association-of-urology-guidelinesmonthly0.5https://www.proteomedix.com/en/news/43/results-published-demonstrating-accurate-diagnosis-of-prostate-cancer-by-combining-proclarix-with-magnetic-resonance-imagingmonthly0.5https://www.proteomedix.com/en/news/42/proteomedix-receives-ivdr-certification-for-proclarixmonthly0.5https://www.proteomedix.com/en/news/41/proteomedix-announces-grant-of-chinese-patent-on-proclarixmonthly0.5https://www.proteomedix.com/en/news/40/side-by-side-evaluation-of-proclarix-and-the-prostate-health-index-phi-for-the-identification-of-clinically-significant-prostate-cancermonthly0.5https://www.proteomedix.com/en/news/39/proteomedix-announces-grant-of-us-patent-on-proclarixmonthly0.5https://www.proteomedix.com/en/news/38/new-results-on-proclarix-resolving-indeterminate-magnetic-resonance-imaging-mri-for-improved-prostate-cancer-diagnosis-will-be-presented-at-the-37th-annual-eau-congress-in-amsterdam-nlmonthly0.5https://www.proteomedix.com/en/news/37/the-biodiagnostica-montevergine-malzoni-network-in-mercogliano-will-introduce-proclarix-into-its-laboratory-routinemonthly0.5https://www.proteomedix.com/en/news/36/new-clinical-data-published-from-proclarix-together-with-magnetic-resonance-imaging-mri-for-improved-prostate-cancer-diagnosismonthly0.5https://www.proteomedix.com/en/news/35/clinical-data-published-of-a-novel-serum-biomarker-quintet-that-improves-disease-prognosis-in-men-with-confirmed-prostate-cancermonthly0.5https://www.proteomedix.com/en/news/34/proteomedix-presents-at-the-annual-congress-of-the-italian-society-of-urology-in-riccione-and-the-society-of-urologists-in-private-hospitals-in-modenamonthly0.5https://www.proteomedix.com/en/news/33/proteomedix-praesentiert-sich-an-der-jahresversammlung-der-schweizerischen-gesellschaft-fuer-urologie-in-interlakenmonthly0.5https://www.proteomedix.com/en/news/32/proteomedix-and-new-horizon-health-limited-enter-into-a-research-and-development-partnershipmonthly0.5https://www.proteomedix.com/en/news/31/proteomedix-praesentiert-sich-am-jahreskongress-der-deutschen-gesellschaft-fuer-urologie-in-stuttgartmonthly0.5https://www.proteomedix.com/en/news/30/new-spanish-clinical-data-from-proclarix-together-with-magnetic-resonance-imaging-mri-for-improved-prostate-cancer-diagnosis-will-be-presented-at-the-36th-annual-european-urology-congressmonthly0.5https://www.proteomedix.com/en/news/29/university-of-naples-federico-ii-is-implementing-and-evaluating-proclarix-to-make-it-available-in-italymonthly0.5https://www.proteomedix.com/en/news/27/zhengzhou-university-henan-cancer-hospital-zuhch-and-proteomedix-enter-into-a-cooperation-to-clinically-validate-biomarker-tests-and-bioinformatics-for-prostate-cancer-diagnosticsmonthly0.5https://www.proteomedix.com/en/news/26/results-published-of-propose-a-real-life-prospective-study-of-proclarix-a-novel-blood-based-test-to-support-challenging-biopsy-decision-making-in-prostate-cancermonthly0.5https://www.proteomedix.com/en/news/25/swiss-center-for-laboratory-medicine-st-gallen-presents-data-from-proclarix-at-american-association-for-clinical-chemistry-aacc-annual-scientific-meetingmonthly0.5https://www.proteomedix.com/en/news/24/university-hospital-frankfurt-mvz-gmbh-first-laboratory-offering-proclarix-in-germanymonthly0.5https://www.proteomedix.com/en/news/23/bestaetigung-der-diagnostischen-leistungsfaehigkeit-des-ersten-schweizer-tests-zur-biopsie-entscheidung-in-der-prostatakrebs-diagnostikmonthly0.5https://www.proteomedix.com/en/news/21/verbesserte-prostatakrebsdiagnostik-ein-ueberblick-im-magazin-der-schweizerischen-union-fuer-labormedizinmonthly0.5https://www.proteomedix.com/en/news/20/proteomedix-appoints-dr-maurizio-ballerini-md-as-vp-market-development-emea-and-dr-helene-peyro-saint-paul-md-as-medical-advisormonthly0.5https://www.proteomedix.com/en/news/19/analytical-performance-of-proclarix-verifiedmonthly0.5https://www.proteomedix.com/en/news/18/proteomedix-and-dynex-technologies-enter-into-strategic-alliance-to-provide-automated-workflows-for-proclarixmonthly0.5https://www.proteomedix.com/en/news/7/center-for-laboratory-medicine-st-gallen-is-the-first-laboratory-to-offer-proclarixmonthly0.5https://www.proteomedix.com/en/news/12/proteomedix-announces-commercial-launch-of-proclarix-in-europemonthly0.5https://www.proteomedix.com/en/news/22/new-data-from-proclarix-together-with-magnetic-resonance-imaging-mri-for-improved-prostate-cancer-diagnosis-to-be-showcased-at-american-society-of-clinical-oncology-asco-genitourinary-cancers-symposiummonthly0.5https://www.proteomedix.com/en/news/1/proteomedix-appoints-helge-lubenow-as-new-ceomonthly0.5https://www.proteomedix.com/en/news/2/proteomedix-today-announced-the-appointment-of-prof-em-dr-med-thomas-cerny-as-new-member-of-the-board-of-directorsmonthly0.5https://www.proteomedix.com/en/news/3/new-publication-confirms-that-the-use-of-proteomedix-proprietary-blood-based-biomarkers-improves-clinically-significant-prostate-cancer-diagnosismonthly0.5https://www.proteomedix.com/en/news/4/proteomedix-raises-chf-52-million-in-financing-roundmonthly0.5https://www.proteomedix.com/en/news/5/novel-biomarker-test-avoids-biopsies-by-accurately-predicting-high-grade-prostate-cancermonthly0.5https://www.proteomedix.com/en/news/6/new-publication-describes-the-development-and-clinical-testing-of-proteomedix-immunoassays-for-prostate-cancer-diagnosismonthly0.5